Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-A, non-B hepatitis: research progress and current perspectives.

D W Bradley, J E Maynard

    Developments in Biological Standardization
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Hepatitis E virus infection in chimpanzees: a retrospective analysis.

    Archives of virology·2000
    Same author

    Pressure cycling technology: a novel approach to virus inactivation in plasma.

    Transfusion·2000
    Same author

    Hepatitis viruses: their role in human cancer.

    Proceedings of the Association of American Physicians·1999
    Same author

    Studies of non-A, non-B hepatitis and characterization of the hepatitis C virus in chimpanzees.

    Current topics in microbiology and immunology·1999
    Same author

    At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain.

    Vaccine·1999
    Same author

    The introduction of new vaccines into developing countries.

    Vaccine·1999
    Same journal

    International challenges and public policy issues.

    Developments in biological standardization·2000
    Same journal

    Regulation of biologicals in China.

    Developments in biological standardization·2000
    Same journal

    ICH activities on biotech topics.

    Developments in biological standardization·2000
    Same journal

    Regulation of biologicals in the European Union.

    Developments in biological standardization·2000
    Same journal

    Standardisation and licensing of combination vaccines based on DTP.

    Developments in biological standardization·2000
    Same journal

    Control of foot-and-mouth disease by vaccination.

    Developments in biological standardization·2000
    See all related articles

    Two transmissible agents cause posttransfusion non-A, non-B hepatitis, often leading to chronic liver disease. Ultrastructural changes in chimpanzees resemble RNA virus infections, impacting hepatitis A and B virus co-infections.

    Area of Science:

    • Hepatology
    • Virology
    • Infectious Diseases

    Background:

    • Posttransfusion non-A, non-B hepatitis (NANB) is a significant clinical concern.
    • The disease can lead to chronic liver conditions and persistent viral presence.
    • Existing serologic tests face challenges due to low viral concentrations and lack of potent antibodies.

    Purpose of the Study:

    • To investigate the characteristics of NANB hepatitis agents.
    • To analyze ultrastructural changes in infected hepatocytes.
    • To determine potential interactions with other hepatitis viruses.

    Main Methods:

    • Experimental inoculation of chimpanzees with NANB hepatitis agents.
    • Ultrastructural examination of infected chimpanzee hepatocytes.

    Related Experiment Videos

  • Observation of co-infection dynamics with Hepatitis A virus (HAV) and Hepatitis B virus (HBV).

    • Main Results:

    • At least two distinct transmissible agents of NANB hepatitis have been identified.
    • Ultrastructural changes in hepatocytes were primarily cytoplasmic, resembling RNA virus-induced alterations.
    • One NANB agent demonstrated interference with concurrent HAV or HBV infection in chimpanzees.

    Conclusions:

    • NANB hepatitis is caused by at least two transmissible agents.
    • The observed cellular changes suggest an RNA virus etiology for NANB hepatitis.
    • NANB agents can modulate the course of other hepatitis virus infections.